COPD exacerbations in the phase 3 revefenacin clinical trial program

J. Donohue (Chapel Hill, NC, United States of America), S. Sethi (Buffalo, NY, United States of America), C. Barnes (South San Franscico, CA, United States of America), E. Moran (South San Franscico, CA, United States of America), S. Pendyala (South San Franscico, CA, United States of America), G. Crater (South San Franscico, CA, United States of America), B. Haumann (London, UK, United Kingdom)

Source: International Congress 2018 – Clinical trials in COPD: new results
Session: Clinical trials in COPD: new results
Session type: Oral Presentation
Number: 1655
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Donohue (Chapel Hill, NC, United States of America), S. Sethi (Buffalo, NY, United States of America), C. Barnes (South San Franscico, CA, United States of America), E. Moran (South San Franscico, CA, United States of America), S. Pendyala (South San Franscico, CA, United States of America), G. Crater (South San Franscico, CA, United States of America), B. Haumann (London, UK, United Kingdom). COPD exacerbations in the phase 3 revefenacin clinical trial program. 1655

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: